Resistance to BRAF Inhibition in Melanomas

被引：188
|
作者：
Solit, David B. [1 ]
Rosen, Neal [1 ,2 ]
机构：
[1] Mem Sloan Kettering Canc Ctr, Dept Med, New York, NY 10021 USA
[2] Mem Sloan Kettering Canc Ctr, Dept Mol Pharmacol & Chem, New York, NY 10021 USA
来源：
NEW ENGLAND JOURNAL OF MEDICINE | 2011年 / 364卷 / 08期
关键词：
RAF; PATHWAY; CRAF;
D O I：
10.1056/NEJMcibr1013704
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
[No abstract available]
引用
收藏
页码：772 / 774
页数：3
相关论文
共 50 条
  • [21] BRAF Fusions Are Characteristic Spitzoid Melanomas
    Jones, David
    Carlson, Andrew
    Wang, Kai
    Tarasen, Ashley
    Sheehan, Christine
    Ali, Siraj
    Elvin, Julla
    Chmielecki, Jullann
    Yelensky, Roman
    Lipson, Doron
    Miller, Vincent
    Stephens, Philip
    Ross, Jeffrey
    [J]. MODERN PATHOLOGY, 2015, 28 : 122A - 122A
  • [22] Determinants of BRAF mutations in primary melanomas
    Maldonado, JL
    Fridlyand, J
    Patel, H
    Jain, AN
    Busam, K
    Kageshita, T
    Ono, T
    Albertson, DG
    Pinkel, D
    Bastian, BC
    [J]. JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2003, 95 (24) : 1878 - 1880
  • [23] BRAF Fusions Are Characteristic Spitzoid Melanomas
    Jones, David
    Carlson, Andrew
    Wang, Kai
    Tarasen, Ashley
    Sheehan, Christine
    Ali, Siraj
    Elvin, Julia
    Chmielecki, Juliann
    Yelensky, Roman
    Lipson, Doron
    Miller, Vincent
    Stephens, Philip
    Ross, Jeffrey
    [J]. LABORATORY INVESTIGATION, 2015, 95 : 122A - 122A
  • [24] Phenotype switching as a resistance mechanism to BRAF and MEK inhibition
    Cheng, P. F.
    Freiberger, S. N.
    Irmisch, A.
    Dummer, R.
    Levesque, M. P.
    [J]. EXPERIMENTAL DERMATOLOGY, 2018, 27 (03) : E91 - E92
  • [25] Resistance to RAF Inhibition in BRAF Mutant Colorectal Cancer
    Corcoran, Ryan B.
    [J]. ONCOLOGIST, 2012, 17 : 2 - 2
  • [26] Absence of BRAF gene mutations in uveal melanomas in contrast to cutaneous melanomas
    Edmunds, SC
    Cree, IA
    Dí Nícolantonío, F
    Hungerford, JL
    Hurren, JS
    Kelsell, DP
    [J]. BRITISH JOURNAL OF CANCER, 2003, 88 (09) : 1403 - 1405
  • [27] Reverse transcriptase inhibition potentiates target therapy in BRAF-mutant melanomas: an in vitro study
    Fattore, Luigi
    Sbardella, Gianluca
    Botti, Gerardo
    Mancini, Rita
    Ascierto, Paolo A.
    Ciliberto, Gennaro
    [J]. JOURNAL OF TRANSLATIONAL MEDICINE, 2021, 19 (SUPPL 1)
  • [28] Dual MAPK Inhibition Is an Effective Therapeutic Strategy for a Subset of Class II BRAF Mutant Melanomas
    Dankner, Matthew
    Lajoie, Mathieu
    Moldoveanu, Dan
    Tan-Trieu Nguyen
    Savage, Paul
    Rajkumar, Shivshankari
    Huang, Xiu
    Lvova, Maria
    Protopopov, Alexei
    Vuzman, Dana
    Hogg, David
    Park, Morag
    Guiot, Marie-Christine
    Petrecca, Kevin
    Mihalcioiu, Catalin
    Watson, Ian R.
    Siegel, Peter M.
    Rose, April A. N.
    [J]. CLINICAL CANCER RESEARCH, 2018, 24 (24) : 6483 - 6494
  • [29] Acquired Resistance to BRAF Inhibition Can Confer Cross-Resistance to Combined BRAF/MEK Inhibition (vol 132, pg 1850, 2012)
    Gowrishankar, Kavitha
    Snoyman, Stephanie
    Pupo, Gulietta M.
    Becker, Therese M.
    Kefford, Richard F.
    Rizos, Helen
    [J]. JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2013, 133 (10) : 2493 - 2493
  • [30] Absence of BRAF gene mutations in uveal melanomas in contrast to cutaneous melanomas
    S C Edmunds
    I A Cree
    F Dí Nícolantonío
    J L Hungerford
    J S Hurren
    D P Kelsell
    [J]. British Journal of Cancer, 2003, 88 : 1403 - 1405
12345